EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Matthew T Wheeler iD, Daniel Jacoby, Perry M Elliott iD, Sara Saberi, Sheila M Hegde, Neal K Lakdawala, Jonathan Myers, Amy J Sehnert, Jay M Edelberg, Wanying Li, Iacopo Olivotto

European Journal of Heart Failure · 2023

DOI: 10.1002/ejhf.2737 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Matthew T Wheeler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Center for Inherited Cardiovascular Disease, Stanford University, Stanford, CA, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Heart Failure. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MyoKardia, Inc., MyoKardia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In the EXPLORER-HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart Association (NYHA) class, were greater in patients not receiving background beta-blockers than in those receiving beta-blockers. We sought to determine if the effect of background treatment was consistent across other clinically meaningful parameters. Methods and results Subgroup analyses by beta-blocker use were performed in patients with oHCM from the EXPLORER-HCM and mavacamten long-term extension (MAVA-LTE) studies. In EXPLORER-HCM, 189 patients (75.3%) were receiving beta-blockers, and 62 (24.7%) were receiving non-dihydropyridine calcium channel blockers or no background HCM medication; 170 patients (90.4%) receiving beta-blockers had chronotropic incompetence. Improvements in peak VO2 at week 30 with mavacamten versus placebo were lower with beta-blockers (mean difference [95% confidence interval (CI)]: 1.04 [0.12, 1.95] ml/kg/min) than without beta-blockers (mean difference [95% CI]: 2.69 [1.29, 4.09] ml/kg/min); improvements in non-heart rate-dependent parameters (VE/VCO2 slope) appeared unaffected by beta-blockers. Improvements in functional capacity parameters at week 30 with mavacamten versus placebo were independent of beta-blockade for post-exercise left ventricular outflow tract gradient (mean difference [95% CI]: −37.9 [−48.0, −27.9] mmHg with beta-blockers; −33.5 [−53.6, −13.3] mmHg without beta-blockers), proportion of patients with reduction of ≥1 NYHA class, Kansas City Cardiomyopathy Questionnaire clinical summary scores and N-terminal pro-B-type natriuretic peptide. Mavacamten benefits were reproduced and maintained in MAVA-LTE regardless of beta-blockade.

Conclusion

Mavacamten improved measures of functional capacity, left ventricular outflow tract obstruction, symptom burden and biomarkers in patients with HCM regardless of beta-blocker use. Beta-blocker use was often associated with chronotropic incompetence, affecting peak VO2 and other heart rate-dependent measures, but had minimal impact on heart rate-independent measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHeart FailureHumansAdrenergic beta-AntagonistsBenzylaminesHeartUracil

Stichwörter der Autor:innen

Beta-blockersExercise capacityMavacamtenObstructive hypertrophic cardiomyopathySymptoms

Substanzen

Adrenergic beta-AntagonistsBenzylaminesMYK-461Uracil

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Center for Inherited Cardiovascular Disease, Stanford University, Stanford, CA, USA.
  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, CT, USA.
  • University College London & St. Bartholomew's Hospital, London, UK.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Cardiology, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA.

ORCID-Profile: Matthew T Wheeler, Perry M Elliott

Förderung

  • MyoKardia, Inc.
  • MyoKardia

Zitieren

APA

Wheeler, M. T., Jacoby, D., Elliott, P. M., Saberi, S., Hegde, S. M., Lakdawala, N. K., Myers, J., Sehnert, A. J., Edelberg, J. M., Li, W., & Olivotto, I. (2023). Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2737

Vancouver

Wheeler MT, Jacoby D, Elliott PM, Saberi S, Hegde SM, Lakdawala NK, et al. Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2737

BibTeX
@article{Wheeler2023,
  author = {Wheeler, Matthew T and Jacoby, Daniel and Elliott, Perry M and Saberi, Sara and Hegde, Sheila M and Lakdawala, Neal K and Myers, Jonathan and Sehnert, Amy J and Edelberg, Jay M and Li, Wanying and Olivotto, Iacopo},
  title = {Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy},
  journal = {European Journal of Heart Failure},
  year = {2023},
  doi = {10.1002/ejhf.2737}
}
Kostenlos starten →